STERIS plc $STE Stock Holdings Trimmed by Keybank National Association OH

Keybank National Association OH lowered its position in shares of STERIS plc (NYSE:STE) by 14.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 14,598 shares of the medical equipment provider’s stock after selling 2,453 shares during the quarter. Keybank National Association OH’s holdings in STERIS were worth $3,228,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Nordea Investment Management AB grew its position in STERIS by 259.0% in the 4th quarter. Nordea Investment Management AB now owns 51,602 shares of the medical equipment provider’s stock valued at $13,165,000 after buying an additional 37,228 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of STERIS by 5.3% in the 3rd quarter. Legal & General Group Plc now owns 693,116 shares of the medical equipment provider’s stock worth $171,505,000 after acquiring an additional 34,981 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of STERIS by 40.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 633,530 shares of the medical equipment provider’s stock worth $160,613,000 after acquiring an additional 183,680 shares during the period. Groupama Asset Managment bought a new position in shares of STERIS in the third quarter valued at approximately $1,163,000. Finally, Cerity Partners LLC increased its stake in shares of STERIS by 116.7% during the fourth quarter. Cerity Partners LLC now owns 209,923 shares of the medical equipment provider’s stock valued at $53,220,000 after acquiring an additional 113,070 shares during the period. Institutional investors own 94.69% of the company’s stock.

STERIS Stock Down 0.1%

NYSE STE opened at $217.94 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The company’s 50 day simple moving average is $211.91 and its 200 day simple moving average is $231.67. STERIS plc has a 12 month low of $195.14 and a 12 month high of $269.44. The company has a market capitalization of $21.24 billion, a P/E ratio of 27.48 and a beta of 0.92.

STERIS (NYSE:STE) last released its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the company earned $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities research analysts expect that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Stockholders of record on Monday, June 8th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is currently 31.78%.

Insider Transactions at STERIS

In related news, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction on Friday, June 5th. The stock was sold at an average price of $212.00, for a total value of $291,288.00. Following the transaction, the chief executive officer directly owned 63,647 shares in the company, valued at $13,493,164. The trade was a 2.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the sale, the director directly owned 38,964 shares in the company, valued at $8,163,347.64. This trade represents a 3.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 7,328 shares of company stock valued at $1,554,051 in the last three months. 1.12% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on STE shares. Piper Sandler restated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research report on Thursday, May 21st. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Finally, KeyCorp cut their price objective on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.